Abbot Pharm bought Solvay Pharm last year at this time (Feb 2010). Abbot is a US company based outside of Chicago.

Press Release
Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Ongoing Earnings Outlook for 2011
Date: January 26, 2011  

* Worldwide Sales Increased 13.4 Percent
* Fourth Quarter Ongoing EPS Growth of 10.2 Percent
* Worldwide Pharmaceutical Sales Increased 22.5 Percent
* Worldwide Vascular Products Sales Increased 13.7 Percent
* U.S. Diagnostics Sales Increased 8.5 Percent

January 26, 2011

Abbott Park, Illinois (NYSE: ABT) — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.
.....................

Across its businesses, Abbott has more than 350 clinical trials underway and expects to deliver more than 75 new products or indications over the next five years. In 2010, we added a total of four new molecular entities that are in late-stage development, and expect to have nearly 20 new molecular entities and indications in Phase 2 or 3 development by the end of 2011. We also expect numerous new trial starts and new data presentations throughout the year. Following are select highlights from breakthrough research across both pharmaceuticals and medical products pipelines:
..............

* Neuroscience / Pain
o Abbott is conducting innovative research in neuroscience, where it has developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions. Abbott has more than a dozen new molecular entities in clinical trials for conditions such as schizophrenia, pain, Alzheimer's disease, Parkinson's disease and multiple sclerosis (MS). This includes three compounds in development for Alzheimer's.
o Abbott's neuroscience pipeline includes a novel, next-generation antibody, daclizumab, which entered Phase 3 development in 2010 for relapsing remitting MS (RRMS), the most common form of the disease.
o Abbott is pursuing compounds that could provide relief across a broad spectrum of pain states, such as chronic back pain, postoperative pain and cancer pain.

That's all I came up with in my research.
Whether they choose to develop the duodopa further or not is now at their discretion.
BTW- a 120 year old megolithic global company whose founder developed and distributed across the planet... wait for it...... SIMILAC!